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Aluminum-containing adjuvants usually referred as Alum are considered as T helper 
type-2 (Th2) adjuvants, while agonists of toll-like receptors (TLRs) are viewed as adjuvants 
that favor Th1/Th17 immunity. Alum has been used in numerous vaccine formulations; 
however, its undesired pro-Th2 adjuvant activity constitutes a caveat for Alum-based 
vaccines. Combining Alum with TLR-dependent, pro-Th1/Th17 adjuvants might dampen 
the pro-Th2 activity and improve the effectiveness of vaccine formulations. Here, using the 
ovalbumin (OVA) model of allergic lung inflammation, we found that sensitization with the 
synthetic TLR9 agonist, which is composed of oligodeoxynucleotides containing CpG 
motifs adsorbed to Alum, inhibited the development of OVA-induced lung allergic Th2 
responses without shifting toward a Th1 pattern. The conversion of T cell immunity from 
the polarized allergic Th2 response to a non-polarized form by sensitization with OVA/
Alum/CpG was dependent on MyD88 signaling in myeloid cells. Notably, sensitization of 
IL-10-deficient mice with OVA/Alum/CpG resulted in the development of neutrophilic lung 
inflammation associated with IFNγ production. However, in IL-10/IL-12-deficient mice, 
it resulted in neutrophilic inflammation dominated by IL-17 production. We conclude 
that OVA/Alum/CpG sensitization signaling via MyD88 and IL-10 molecules results in 
non-polarized immunity. Conversely, OVA/Alum/CpG sensitization in presence of MyD88 
but absence of IL-10 or IL-10/IL-12 molecules results, respectively, in neutrophilic 
inflammation associated with IFNγ or IL-17 production. Our work provides novel OVA 
models of lung inflammation and suggests that Alum/CpG-based formulations might be 
of potential use in anti-allergic or anti-infectious processes.
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inTrODUcTiOn
Adjuvants (from Latin, adjuvare: to help) can be broadly categorized in two major functional 
groups based on whether their immune activity is dependent or not on toll-like receptor (TLR) 
signaling. Aluminum-containing adjuvants, usually referred as Alum, are TLR-independent adju-
vants used in numerous vaccine formulations such as the triple vaccine (diphtheria, pertussis, and 
tetanus), human papillomavirus, and hepatitis vaccines (1, 2). Although Alum has been licensed 
for human vaccines for almost 100  years, studies on the mechanisms of action and signaling 
underlying its activity are still in progress (1, 3, 4). Alum has been extensively used in the classical 
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ovalbumin (OVA) asthma model because sensitization with this 
adjuvant provokes strong antigen-induced T helper type-2 (Th2) 
responses, characterized by infiltration of effector/inflammatory 
CD4+ T cells and eosinophils into the lung and elevated serum 
IgE levels (5).
Accumulating evidence indicates that adjuvants act in 
the early stages of the immune response by activating innate 
immune responses, which are responsible for driving the 
polarization of naïve CD4+ T cells toward effector inflam-
matory Th2, Th1, or Th17 cells (6). Various mechanisms 
and pathways have been advanced to explain how Alum 
potentiates Th2 activity, among them, IL-4 production by 
splenic Gr-1+ myeloid cell type, conversion of soluble antigen 
to a particulate form, production of IL-1β via activation of 
NLRP3-inflammassome, release of DNA from dying host cells, 
induction of uric acid, secretion of prostaglandin PGE2, and 
others [reviewed in Ref. (2, 3)]. By contrast, the molecular 
mechanisms of TLR signaling are well characterized and 
involve the activation of two main downstream signaling path-
ways: the MyD88- and TRIF-dependent pathways. Some TLR 
agonists such as monophosphoryl lipid A (MPLA), a TRIF-
biased TLR4 agonist, or TLR9 agonists, which are composed of 
oligodeoxynucleotides (ODN) containing CpG motifs (CpG), 
have been approved for use in humans (4).
A caveat of Alum-based vaccines might be the undesired pro-
Th2 adjuvant activity of Alum. It is postulated that targeting the 
innate immune system by combining multiple stimuli, such as 
those generated by TLR-dependent and independent adjuvants, 
might dampen the pro-Th2 activities of Alum and boost the effec-
tiveness of vaccines (2). Indeed, using the OVA asthma model, 
we have previously shown that sensitization with TLR4 agonists, 
adsorbed to Alum, dampens the development of OVA-induced 
allergic lung Th2 responses without inducing a shift toward a 
Th1 lung inflammation (7). Importantly, we recently showed that 
adsorption of a TLR4 agonist to Alum-based tetanus toxoid vac-
cine also dampens toxoid-induced Th2 cellular responses and IgE 
production, and enhances humoral IgG antibody responses (8). 
Thus, it appears that antigen sensitization with two types of adju-
vants results in a non-polarized cellular immunity that activates 
and modifies quantitatively and qualitatively B cell antibody help.
Since CpG-ODN, a synthetic TLR9 agonist, is another 
adjuvant approved for use in humans (4), we extended our work 
and studied the effect of sensitization to OVA with CpG-ODN, 
type C, adsorbed to Alum. Cellular immunity was determined 
by the phenotype of lung-infiltrating effector/inflammatory 
CD4+ T cells after intranasal (i.n.) OVA challenge and humoral 
immunity was determined in serum by total IgE production and 
OVA-specific antibody isotypes.
We found that addition of CpG to Alum attenuated dose-
dependently the Th2 sensitization in wild-type (WT) mice. The 
expression of the MyD88 adaptor molecule on myeloid cells was 
sufficient to mediate the inhibitory effect on Th2 sensitization. 
Notably, in IL-10-deficient animals, OVA sensitization with 
Alum/CpG-adjuvant resulted in the development of neutrophilic 
airway inflammation associated with IFNγ production, while in 
IL-10/IL-12p40 double-knockout (KO) mice it was associated 
with IL-17 production.
Our results indicate that OVA sensitization with Alum/
CpG formulation induces T helper phenotypes ranging from 
non-polarized to IFNγ or IL-17-dominated lung inflammation, 
depending on MyD88 signaling and the cytokine milieu.
Our study highlights the major signaling pathways involved in 
adjuvant activities of an Alum-based CpG formulation and sug-
gests its potential use for the development of vaccines or immu-
notherapies aiming at multiple T helper cell effector functions.
MaTerials anD MeThODs
Mice
The 6- to 12-week-old female C57BL/6 or 129 Sv mice were 
used. C57BL/6 WT, MyD88-KO, IL-10-KO, IL-12p40-KO, 
IFNγ-KO, and RAG-KO mice on C57BL/6 background were 
originally purchased from Jackson Laboratories (Bar Harbor, 
ME, USA). Double KOs IL-10/IL-12p40-KO or IL-12p40/
IFNγ-KO mice were generated in our breeding unit. The 129 
Sv WT, IFNα/β receptor (IFNα/βR)-KO, and IFNγ receptor 
(IFNγR)-KO mice on 129 Sv background (9) were provided by 
Dr. Luiz Fernando Reis (Ludwig Institute for Cancer Research, 
São Paulo, Brazil).
Mice were kept at specific pathogen-free breeding unit, 
Institute of Biomedical Sciences (ICB IV-USP), in five animals 
per cage in a ventilated caging system with filter tops under a 
laminar flow hood. Twelve-hour light/dark cycle, temperature-
controlled rooms, food and water ad  libitum, cardboard tubes, 
and towel paper were used for environment enrichment. Mice 
were treated according to animal welfare guidelines of ICB (Ethic 
Protocol 081/09) under National Legislation-11.794 Law.
reconstitution rag-KO Mice with 
lymphoid cells
RAG-KO mice received 20 ×  106 spleen cells diluted in sterile 
phosphate buffer saline (PBS) via intraperitoneal (i.p.) route 
from spleen macerates of WT or MyD88-KO mice. Reconstituted 
RAG-KO mice were used 14 days later.
sensitization and challenge
Mice were subcutaneously (s.c.) sensitized on days 0 and 7 
with 4 µg of OVA adsorbed to 1.6 mg of Al(OH)3 (Alum) gel in 
0.2 mL of PBS, containing or not TLR agonists. TLR4 agonist 
(LPS from Escherichia coli 055:B5) was purchased from Sigma-
Aldrich (St. Louis, MO, USA) and TLR9 agonist (CpG-ODN 
2395 Class C) from Invivogen (San Diego, CA, USA). The 
standard dose of TLR ligands was 10 µg. On days 14 and 21, 
mice were intra-nasally challenged with OVA (10 µg) in 40 µL of 
PBS. Control mice consisted of naïve non-manipulated animals. 
Sensitization and challenge were done under anesthesia with 
ketamine (50  mg/kg) and xylazine (20  mg/kg). Animals were 
euthanized by inhaled halothane 24 h after the last challenge; 
samples were collected, unaware numbered, and decoded after 
analyses.
Endotoxin (LPS) removal from OVA and Alum preparation 
was performed as previously described (7). Briefly, chicken 
OVA (Sigma-Aldrich, St. Louis, MO, USA) was diluted in PBS 
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(2 mg/mL) and depleted of the endotoxin activity (measured by 
Limulus amoebocyte lysate QCL-1000 kit from BioWhittaker, 
Walkersville, MD, USA), using two to four cycles of Triton X-114 
extractions, as described by Aida and Pabst (10). The endotoxin 
level of purified OVA (2 mg/mL) was below the limit of detection 
(less than 0.1 EU).
serum samples and Bronchoalveolar 
lavage (Bal)
Blood samples were collected by cardiac puncture, centrifuged, 
and serum stored was at −20°C. BAL was acquired after lung wash-
ing with 1 mL of cold PBS via the trachea. Total and differential 
cell counts of BAL fluids were determined by haemocytometer 
and cytospin preparation stained with Instant-Prov (Newprov, 
Brazil) or with Panótico-Rápido (Laborclin, Brazil), both stains 
based on Romanowsky formulation.
enzyme-linked immunosorbent assay 
(elisa) for antibodies and cytokine 
Determinations
Total mouse IgE was determined by sandwich-ELISA using kit 
BD OptEIA ELISA Set (BD, San Diego, CA, USA). OVA-specific 
IgE was determined by adding serum at multiple dilutions to 
plates with anti-IgE (SouthernBiotech, Birmingham AL, USA). 
After washing, biotin-labeled OVA was added and revealed with 
avidin-HRP plus substrate. Internal sample arbitrarily assigned 
as 1,000  U was used as standard. OVA-specific IgG2a/c were 
measured by coating the plates with 20 µg/mL of OVA. Serum 
samples were added at multiple dilutions and revealed with goat 
anti-mouse IgG2a conjugated to HRP (Invitrogen, San Diego, 
CA, USA), which also reacts with IgG2c isotype. Purified mouse 
IgG2a (Southern Biotech) was used as standard. All ELISA 
were performed in 96-well maxisorp plates (Nunc, NY, USA). 
Cytokines levels were assayed by sandwich kit ELISA accord-
ing to the manufacturer’s recommendation (BD Biosciences, 
PharMingen, San Diego, CA, USA) as previously described (5). 
Values were expressed as picograms per milliliter deduced from 
a standards curve of recombinant cytokines ran in parallel. The 
limits of detection ranged from 5 to 30 pg/mL.
Flow cytometry analysis
Three lobules (superior, middle, and post caval) of right lungs 
were digested with collagenase IV (2  mg/mL) and DNAse I 
(1  mg/mL) (Sigma-Aldrich), at 37°C for 30  min. Cell suspen-
sion was obtained after erythrocyte lysis. Extra-cellular stain-
ing to identify neutrophils and eosinophils was done using 
fluorochrome-conjugated antibodies (BD, San Diego CA, USA): 
anti-CD45 (C363.16A), -Gr-1 (RB6-8C5), -siglecF (E50-2440), 
and anti-major histocompatibility complex class II (MHC-II) 
(107630) (Biolegend, San Diego, CA, USA). For each sample, at 
least 1,000,000 events were collected. Cytokine production by 
lung cells was determined after stimulation of cells in vitro with 
10 ng/mL PMA (phorbol 12-myristate 13-acetate) and 750 ng/
mL ionomicin (Sigma-Aldrich, St. Louis, MO, USA) incubated 
with GolgiStop (BD-Biosciences, San Diego, CA, USA) for 12 h 
at 37°C in RPMI-1640 medium. Cell suspensions were stained 
with fluorochrome-conjugated antibodies against surface mark-
ers CD45 (C363.16A), CD3 (145-2C11), and CD4 (RM4-5). 
Cells were permeabilized and subsequently fixed with Cytofix/
Cytoperm kit with GolgiPlug (BD-Biosciences, San Diego, CA, 
USA). For intracellular cytokine staining, we used antibodies 
against IL-4, IFNγ, and IL-10 (BD, San Diego, CA, USA). Only 
viable and non-doublet cells were considered. Cell acquisition 
was performed on a FACs CANTO II instrument using FACSDiva 
software (BD, San Diego, CA, USA). For each sample, at least 
300,000 events were collected. Pools of three to five samples from 
the same group were used. Data were analyzed using FlowJo 
software (Tree Star). The number of cytokine-producing CD4+ 
T cells was calculated based on the total number of viable cells 
(trypan blue exclusion test) recovered from digested lung lobules. 
FACS analysis was performed with pooled samples from three to 
five mice.
lung histopathology
Lungs were perfused with 10 mL of cold PBS through the right 
ventricle, fixed in 10% PBS-formalin for 24 h and then in 70% 
ethanol until embedding in paraffin. Five-micrometer sections 
were stained with hematoxylin/eosin or periodic acid-Schiff for 
analysis of cell infiltrates and mucus production, respectively. 
Lung inflammation score was performed in coded samples by 
two researchers scoring peribronchial and perivascular cellular 
infiltrates as: 0 (not present); 1 (<20% of the airways affected); 2 
(20–40%), 3 (40–60%), 4 (60–80%), and 5 (>80% of the airways 
affected) arbitrary units (AU). Mucus score was calculated as the 
percentage (%) of mucus positive bronchi throughout the lung 
sections. In experiments shown in Figure 7, lung inflammation 
was scored by measuring the area of peribronchial infiltrate per 
length of bronchial basal membrane.
1-Methyltryptophan (1-MT) Treatments  
and Determination of indoleamine 
2,3-Dioxygenase (iDO) enzymatic  
activity
1-Methyltryptophan was used to inhibit IDO activity. Three dif-
ferent treatments were performed on OVA/Alum/CpG sensitized 
animals: (a) 30-day slow release 1-MT polymer pellet (150 mg/
pellet) (Innovative Research of America) was inserted under the 
dorsal skin of mice on day 0, as previously described; (b) 1-MT 
(10  mg) (Sigma-Aldrich) diluted in PBS (500  mL) was daily 
injected by i.p. route from day 0 to day 14; or (c) 1-MT (35 mg) 
was absorbed to OVA/Alum/CpG formulation. To estimate IDO 
enzymatic activity in lung, the concentration of kynurenine, an 
IDO metabolite, was measured using a modified spectrophoto-
metric assay (11).
statistical analysis
Statistical analyses were performed using GraphpadPrism (V.5; 
GraphPad Software, USA). One-way ANOVA followed by 
Tukey post-test was performed, as appropriate. Differences were 
considered statistically significant when p value ≤ 0.05. Data are 
presented as mean ± SE.
FigUre 1 | Toll-like receptors 4 and 9 agonists adsorbed to alum prevent T helper type-2 allergic responses. C57BL/6 wild-type mice were sensitized 
with ovalbumin (OVA)/Alum or with OVA/Alum/CpG or with OVA/Alum/LPS on days 0 and 7 and challenged with OVA on days 14 and 21. Samples were obtained 
on day 22. (a) Total cell and (B) differential cell counts in bronchoalveolar lavage (BAL); (c) IL-5 and (D) IFNγ concentrations in BAL. (e) Representative 
microphotographs of periodic acid-Schiff staining and lung mucus score (see Materials and Methods); (F) total IgE and (g) OVA-specific IgE serum levels. Control 
group (n = 4) consisted of non-manipulated animals. OVA/Alum/phosphate buffer saline (PBS) group (n = 10), OVA/Alum/LPS group (n = 5), and OVA/Alum/PBS 
group (n = 5). Values represent the mean ± SD and are representative of three independent experiments. One-way ANOVA: *p < 0.05; **p < 0.01; ****p < 0.0001, 
different from OVA/Alum/PBS group.
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resUlTs
Tlr4 or Tlr9 agonists adsorbed to alum 
Prevent Th2 allergic sensitization
We have previously shown that sensitization to OVA performed 
with TLR4 agonist adsorbed to Alum prevented the development 
of asthma-like responses without shifting the lung inflamma-
tion toward a Th1 pattern (7). Here, we extended our study 
and compared the effect of sensitizations with agonists of TLR4 
(LPS) or TLR9 (CpG) adsorbed to Alum on the development of 
OVA-induced airway allergic disease in WT C57BL/6 mice. We 
found that absorption of LPS or CpG onto OVA/Alum prevented 
airway allergic inflammation. Decreased number of total cells 
and eosinophils were observed in BAL fluid (Figures 1A,B) when 
comparing CpG to allergic group (OVA/Alum). A slight, but sig-
nificant increase in the number of lymphocytes or macrophages 
was observed, respectively, in LPS and CpG groups (Figure 1B). 
The number of infiltrating neutrophils was low and not signifi-
cantly affected by TLR agonists. The levels IL-5 were significantly 
decreased in LPS or CpG groups, but the levels of IFNγ produc-
tion in BAL were not affected (Figures  1C,D). Particularly, 
significant inhibition of mucus production was only observed in 
CpG group when compared to allergic group (Figure 1E). Finally, 
LPS or CpG suppressed total and OVA-specific IgE production 
when compared to allergic group, being CpG superior to LPS in 
suppressing IgE production (Figures  1F,G). We conclude that 
CpG is more effective than LPS in dampening OVA-induced 
Th2-mediated allergic responses.
cpg adsorbed to alum attenuates OVa-
induced airway allergic responses in a 
Dose-Dependent Manner
We next evaluated the effect of different doses of CpG on the 
development of OVA-induced airway allergic disease. WT 
C57BL/6 mice were sensitized to OVA adsorbed to Alum with or 
without CpG, at doses of 0.1, 1, or 10 µg. Figure 2 shows that the 
inhibitory effect of CpG on Th2 responses was dose-dependent 
and even at low CpG dose (0.1 µg), the number of total cells and 
eosinophils in the BAL were reduced (Figures 2A,B) as well as 
lung inflammation and mucus production scores (Figures 2C,D). 
Regarding IgE antibody production, we found that the higher the 
dose of CpG the better the inhibition of total and OVA-specific 
IgE production (Figures  2E,F). OVA-specific IgG2c, a Th1-
associated isotype, was significantly increased at high dose of 
CpG (Figure 2G). Based on the number of total and differential 
FigUre 2 | Tlr9 agonist (cpg) attenuates airway allergic responses 
in a dose-dependent manner. C57BL/6 wild-type mice were sensitized 
with ovalbumin (OVA)/Alum or with CpG at different doses (0.1, 1, or 10 μg/
animal) absorbed to OVA/Alum on days 0 and 7 and challenged with OVA on 
days 14 and 21. Samples were obtained on day 22. (a) Total cell and (B) 
differential cell counts in bronchoalveolar lavage (BAL); (c) lung inflammation 
score by hematoxylin/eosin staining and (D) lung mucus score by periodic 
acid-Schiff staining (see Materials and Methods); (e) total IgE, (F) OVA-
specific IgE, and (g) OVA-specific IgG2c serum levels. The percentage of 
lymphocytes in BAL was less than 10% in all groups. Values represent the 
mean ± SD of one experiment. One-way ANOVA: *p < 0.05; **p < 0.01; 
***p < 0.001; ****p < 0.0001, different from OVA/Alum/phosphate buffer 
saline (PBS) group (n = 5). One-way ANOVA: ••p < 0.01; ••••p < 0.0001, 
different between groups (n = 5).
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cells (Figures 2A,B) and lung inflammatory score (Figure 2C), 
we could not detect any deviation toward Th1-type lung inflam-
mation. Overall, adsorption of CpG to Alum was effective in 
dampening the development of Th2-mediated responses and 
modifying qualitatively humoral immunity without inducing a 
noticeable lung inflammation.
adsorption of cpg-ODn to OVa/alum is 
required for Optimal inhibition of allergic 
sensitization
To evaluate whether the CpG effect on allergic sensitization 
depends on adsorption to Alum, we compared the effect of 
CpG in animals sensitized with CpG adsorbed to OVA/Alum to 
animals that received separately CpG by subcutaneous (on the 
opposite site of OVA/Alum injection) or i.p. routes. PBS (allergic) 
group was used as a positive control. We found that optimal inhi-
bition of allergic sensitization by CpG when compared to PBS 
group requires its absorption to Alum (Figure 3). Specifically, the 
number of total cells and eosinophils in BAL of mice sensitized 
with CpG adsorbed to Alum (CpG group) was more reduced 
than in animals that received CpG separately by s.c. or i.p. routes 
(CpG s.c. and CpG i.p. groups) when compared to PBS group 
(Figures 3A,B). Notably, IgE production and OVA-specific IgE 
antibodies were only significantly reduced in animals sensitized 
with CpG absorbed to OVA/Alum (Figures 3C,D). FACS analysis 
of infiltrating lung CD4+ T cells producing-cytokines showed that 
CpG administration dampened Th2 responses in all CpG groups, 
as revealed by the decreased percentage of IL-4-producing T 
cells when compared to PBS group (Figure 3E) and confirmed 
the superior efficacy of CpG absorbed to Alum in inhibiting Th2 
sensitization since the CpG group showed the lowest value IL-4-
producing T cells when compared to other groups (Figure 3E). 
Importantly and in line with previous results, the percentage 
of IFNγ-producing T cells in all CpG groups did not increase 
when compared to PBS group (Figure 3E) while the percentage 
of IL-10-producing T cells was lower in all CpG groups when 
compared to allergic (PBS) group (Figure  3E). Overall, these 
results clearly indicate that CpG adsorbed to Alum is more effec-
tive in dampening the development of allergic responses than 
when given separately (in a non-absorbed form) during OVA/
Alum sensitization. In addition, the results obtained with lung-
infiltrating CD4+ cytokine-producing T cells (IL-4 versus IFNγ 
or IL-10) reinforce the view that OVA/Alum/CpG sensitization 
inhibits Th2 responses without inducing immune deviation 
toward Th1 pattern or regulatory mechanisms.
attenuation of allergic sensitization by 
cpg requires signaling through MyD88 
Pathway but not il-12/iFnγ axis
It is well established that CpG signals through MyD88 pathway 
(12), although it was recently shown that TRIF pathway could 
also be involved (13). In vivo and in  vitro models have shown 
that CpG induce the release of type 1 cytokines, notably IL-12 
and IFNγ (14), that in turn, downregulate type-2 immune 
responses (15, 16). To determine whether MyD88 pathway and 
type 1 cytokines were involved in the CpG-induced inhibition of 
allergic sensitization, we studied the effect of CpG in MyD88-KO 
or IL-12p40-KO or IL-12p40/IFNγ double-KO mice. We first 
found that OVA/Alum sensitization induced significant airway 
allergic inflammation in MyD88-KO, IL-12-KO, or IL-12/IFNγ 
double KOs mice, as shown by increased number of total cells, 
eosinophils in the BAL, lung mucus production, and total and 
OVA-specific IgE antibody production (Figures 4A–E). Control 
mice did not show these alterations (data not shown). Absorption 
of CpG to Alum (OVA/Alum/CpG group) inhibited the develop-
ment of allergic responses in all KO mice, except MyD88-KO 
mice (Figures 4A–E). These findings indicate that the expression 
of MyD88, but not IL-12/IFNγ molecules, is essential for the 
FigUre 3 | Optimal inhibition of allergic sensitization by cpg requires adsorption to alum. C57BL/6 wild-type mice were sensitized with ovalbumin (OVA)/
Alum [phosphate buffer saline (PBS)] or with OVA/Alum plus CpG absorbed to OVA/Alum (CpG) or given by s.c. (CpG s.c.) or by intraperitoneal (i.p.) route (CpG i.p.) 
on days 0 and 7 and challenged with OVA on days 14 and 21. Samples were obtained on day 22. (a) Total cell and (B) eosinophil cell counts in bronchoalveolar 
lavage (BAL); (c) total IgE and (D) OVA-specific IgE serum levels; (e) FACS analysis of cytokine-producing CD4+ T cells performed with pooled lung cells from three 
animals. Values represent the mean ± SD of one experiment. One-way ANOVA: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001, different from OVA/Alum/PBS 
group (n = 5). One-way ANOVA: ••p < 0.01; ••••p < 0.0001, different between groups (n = 5).
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FigUre 4 | attenuation of allergic sensitization by cpg requires signaling through MyD88 pathway but not il-12/iFnγ axis. MyD88-knockout (KO), 
IL-12-KO, or IL-12/IFNγ-KO mice were sensitized with ovalbumin (OVA)/Alum or with OVA/Alum/CpG on days 0 and 7 and challenged with OVA on days 14 and 21. 
Samples were obtained on day 22. (a) Total cell and (B) eosinophil cell counts in bronchoalveolar lavage (BAL); (c) lung mucus score by periodic acid-Schiff 
staining; (D) total IgE and (e) OVA-specific IgE serum levels. Values represent the mean ± SD and are representative of two experiments. One-way ANOVA: n.s. 
(non-significant), *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001, difference between OVA/Alum and OVA/Alum/CpG (n = 5).
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inhibition of allergic sensitization by CpG. Besides IFNγ, type 
I interferons (IFNs) have also been proposed as mediators of 
the immune modulatory effects of CpG (17). Studies on murine 
models of allergic airway inflammation have shown that IFN-α 
and IFN-β downregulate eosinophil and CD4+ T cell recruitment 
into airways (18, 19). Therefore, to extend our results we also 
included in our study IFNα/βR-KO and IFNγR-KO mice. We 
found that addition of CpG to OVA/Alum reduced airway eosin-
ophilic inflammation, IL-5, and IgE production (Figures S1A–E 
in Supplementary Material), indicating that IFNαβ or IFNγ are 
not critical in the CpG-induced attenuation of allergic responses. 
The induction of IDO enzyme activity is another pathway that 
has been proposed for the inhibition of experimental asthma by 
CpG (13, 20). Therefore, we treated OVA/Alum/CpG sensitized 
animals with 1-MT, an inhibitor of IDO activity, and also moni-
tored IDO activity by measuring kynurenine levels in lung tissue. 
As shown in Figure S2 in Supplementary Material, the inhibitory 
effect of CpG on Th2 immunity was preserved in animals treated 
with 1-MT when compared to untreated animals. In addition, no 
augmented IDO activity was detected in the lung of OVA/Alum/
CpG group (Figure S2 in Supplementary Material). Altogether, 
these results indicate that the role of CpG in inhibiting allergic 
process does not involve type I or type II IFN receptors or IDO 
activity.
MyD88 expression on Myeloid cells is 
sufficient for inhibition of allergic 
sensitization by cpg
Since MyD88 molecule was critical for the inhibitory effect of CpG, 
we next determined the role of MyD88 expression on myeloid 
or adaptive lymphoid cells. For this, we first reconstituted RAG-
1-KO mice, which express MyD88 molecule on myeloid cells 
but lack adaptive mature B and T lymphocytes (21) with spleen 
cells of WT or MyD88-KO mice as depicted in Figures  5A,F. 
Reconstituted RAG-KO mice with WT spleen cells and sensitized 
with OVA/Alum developed allergic eosinophilic inflammation, 
showing increased total and eosinophils cell counts in BAL 
(Figures 5B,C) as well as increased levels of total and specific IgE, 
when compared to non-reconstituted (RAG−/−) or reconstituted 
FigUre 5 | MyD88 expression on adaptive lymphoid cells is not required for inhibition of allergic sensitization by cpg. (a) RAG−/− mice on C57BL/6 
background were reconstituted or not with 20 × 106 spleen cells of C57BL/6 wild-type (WT) or MyD88-knockout (KO) mice. Fourteen days later, mice were 
sensitized with ovalbumin (OVA)/Alum or OVA/Alum/CpG on days 0 and 7 and challenged with OVA on days 14 and 21. Samples were collected on day 22. (a,F) 
Schematic protocol of reconstituted RAG−/− mice with WT or MyD88-KO spleen cells; (B,g) total cell and (c,h) eosinophil cell counts in bronchoalveolar lavage 
(BAL); (D,i) total IgE and (e,J) OVA-specific IgE serum levels; (K,l) lung mucus (periodic acid-Schiff) and inflammation (hematoxylin/eosin) scores (see Materials and 
Methods); RAG−/− group represents non-manipulated RAG−/− mice. Control group represents reconstituted RAG−/− mice without further manipulation. Values 
represent the mean ± SD and a representative of three independent experiments. One-way ANOVA: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001, compared 
to OVA/Alum group (n = 7).
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but non-manipulated (Control) groups (Figures  5D,E). By 
contrast, mice sensitized with OVA/Alum/CpG did not develop 
airway allergic inflammation (Figures  5B,C) and showed 
decreased IgE production when compared to OVA/Alum group 
(Figures 5D,E). As expected, non-reconstituted (RAG−/−) mice 
have no serum IgE (Figure 5D). RAG-KO mice reconstituted with 
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MyD88-KO lymphoid cells and sensitized with OVA/Alum also 
developed allergic eosinophilic inflammation (Figures 5G,H) as 
well as increased levels of total and OVA-specific IgE antibodies 
when compared to control groups (Figures  5I,J). Importantly, 
OVA/Alum/CpG group did not develop airway allergic inflam-
mation and IgE production was decreased when compared to 
OVA/Alum group (Figures 5G–J). Lung mucus and inflamma-
tion scores confirmed the inhibitory effect of CpG on lung allergic 
inflammation in reconstituted RAG-KO mice with MyD88-KO 
lymphoid cells (Figures 5K,L). Therefore, CpG signaling through 
MyD88 pathway on myeloid cells was sufficient to inhibit Alum 
Th2 sensitization.
OVa/alum/cpg sensitization of il-10-KO 
or il-10/il-12-KO Mice induces 
neutrophilic airway inflammation 
Dominated, respectively, by iFnγ or  
il-17 cytokines
Our results indicated that type 1 cytokines or respective recep-
tors were not essential for the inhibition of allergic sensitization 
induced by CpG. Since CpG signaling through MyD88 also trig-
gers the production of IL-10, a molecule that has been shown to 
suppress both Th1 and Th2 responses (22), we turned our focus 
to the role of IL-10 in our model. For this, animals were sensitized 
with OVA/Alum or OVA/Alum/CpG and the results obtained in 
IL-10 KO mice were compared with those obtained in WT mice. 
Both mouse strains developed allergic inflammation when sen-
sitized with OVA/Alum as revealed by total and eosinophil cell 
counts in BAL (Figures 6A,B). However, an apparent difference 
was found between WT and IL-10-KO mice sensitized with OVA/
Alum/CpG, since WT mice did not develop airway inflamma-
tion while IL-10-KO mice developed an intense recruitment of 
inflammatory cells in BAL that was predominantly constituted of 
neutrophils (Figures 6A,B). All CpG groups showed lower IL-4 
production than OVA/Alum groups (Figure 6C) while the levels 
of IL-10 were increased in allergic (OVA/Alum) group but not 
in OVA/Alum/CpG groups and as expected, they were bellow 
detection in IL-10-KO mice (Figure 6D). Importantly, in OVA/
Alum/CpG groups, high levels of IFNγ in BAL were only found 
of IL-10-KO but not in WT mice (Figure 6E). IL-17 levels in BAL 
were bellow detection in all groups (Figure 6F).
These results indicate that, in absence of IL-10, sensitization 
with OVA/Alum/CpG instead of inducing non-polarized immu-
nity results in the development of polarized IFNγ-dominated 
lung inflammation. Because IL-12 is pivotal to induce Th1 
immunity, we also determined the inflammatory phenotype of 
IL-10/IL-12p40 double-KO mice. Double-KO animals sensitized 
with OVA/Alum also developed allergic airway inflammation as 
revealed by total and eosinophil cell counts in BAL (Figures 6A,B). 
Eosinophil cell counts were decreased in CpG group when com-
pared to OVA group (Figure 6B), but CpG group also showed 
increased number of neutrophils in BAL (Figure  6B). Notably 
IL-17, but not IFNγ production was significantly increased only 
in CpG group of IL-10/12-KO mice when compared to OVA/
Alum groups (Figures  6E,F). These results indicate that in 
IL-10 KO mice IFNγ predominate while in IL-10/12-KO mice 
IL-17 predominate in BAL of CpG groups. As shown before, IgE 
production was inhibited while IgG2c production was increased 
in CpG groups when compared to allergic (OVA/Alum) group 
(Figures 6G,H) and in IL-10-KO mice, the production of OVA-
specific IgG2c antibodies reached the highest levels (Figure 6I).
The above results indicate that phenotype of adaptive immu-
nity to OVA resulting from sensitization with OVA/Alum/CpG 
varies depending on the presence of IL-10 and IL-12 cytokines. 
In WT mice, intranasal OVA challenge does not results in lung 
inflammation while in IL-10 KO or IL-10/IL-12-KO mice intra-
nasal OVA challenge induces airway neutrophilic inflammation 
and lung inflammation associated with IFNγ or IL-17 production. 
In order to reveal and quantify lung inflammation, we performed 
histological analysis of lung sections of Control, OVA/Alum, and 
OVA/Alum/CpG groups in WT, IL-10-KO, and IL-10/12-KO 
mice. We found that all OVA/Alum sensitized strains developed 
peribronchial inflammatory infiltrates when compared to respec-
tive Control groups as shown by representative micrographs of 
lung section and lung inflammation scores (Figures  7A,B). In 
WT mice, lung inflammation of mice sensitized with OVA/Alum/
CpG was absent and similar to Control group (Figures 7A,B) while 
in IL-10-KO or IL-10/12-KO mice sensitized with OVA/Alum/
CpG the intensity of lung inflammation was significantly higher 
when compared to Control group (Figures 7A,B). Therefore, we 
conclude that besides MyD88, IL-10 is another molecule that 
plays a critical role in shaping Alum/CpG-adjuvant activity.
DiscUssiOn
In the present study, using an OVA model of lung inflammation, 
we investigated the phenotype of adaptive immunity to OVA 
resulting from sensitizations with an Alum-based formulation 
combined or not with CpG. We found that OVA/Alum sensitiza-
tion always resulted OVA-induced eosinophilic lung inflamma-
tion, which intensity varied from experiment to experiment, but 
that upon absorption of CpG to Alum invariable inhibited its pro-
Th2 adjuvant activity and the consequent development of allergic 
lung inflammation, without shifting toward Th1 immunity. These 
results confirm and extend our previous work with TLR4 agonists 
(7, 8) and in the light of the hygiene hypothesis, we postulate 
that this type of immunological stimuli might be operating in 
individuals exposed to allergens and microbial products. Indeed, 
it has been shown that school children with higher mattress 
concentrations of muramic acid, a broad marker of microbial 
exposure, had significantly lower prevalence of allergy (23).
It has been shown that CpG stimulates dendritic cells (DCs) 
to produce IL-12, which, in turn, induce effector Th1 cells (15). 
Likewise, the inhibitory effect of CpG in asthma models has 
been associated with the stimulation of Th1-type response (24). 
However, our findings do not support this view since we showed 
that Th2 inhibition by CpG was preserved in animals deficient 
in developing Th1 immunity, such as IL-12-KO, IL-12/IFNγ-KO, 
or IFNγ receptor-KO mice. This is in line with previous work 
of Kline et al. showing that Th1 cytokines were not required for 
the suppression of Th2-like immune responses (25). We also 
investigated whether the inhibition of allergic sensitization could 
be mediated by type I IFNs, produced upon CpG stimulation 
FigUre 6 | alum-based cpg sensitization induces, respectively, in il-10-knockout (KO) or il-10/il-12-KO mice airway inflammation dominated by 
iFnγ or il-17. C57BL/6 wild-type and IL-10-KO mice were sensitized with ovalbumin (OVA)/Alum or with OVA/Alum/CpG on days 0 and 7 and challenged with 
OVA on days 14 and 21. Samples were obtained on day 22. (a) Total cell counts and (B) eosinophil and neutrophil numbers in bronchoalveolar lavage (BAL); 
(c) IL-4, (D) IL-10, (e) IFNγ, and (F) IL-17 in BAL; (g) total IgE, (h) OVA-specific IgE, and (i) OVA-specific IgG2c serum levels. Values represent the mean ± SD and 
are representative of two independent experiments. One-way ANOVA: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001, difference between OVA/Alum and OVA/
Alum/CpG (n = 5).
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FigUre 7 | lung histology and lung inflammation score of wild-type 
(WT), il-10-knockout (KO), or il-10/il-12-KO mice. C57BL/6 WT, 
IL-10-KO, or IL-10/IL-12 double-KO mice were sensitized with ovalbumin 
(OVA)/Alum or with OVA/Alum/CpG on days 0 and 7 and challenged with 
OVA on days 14 and 21. Samples were obtained on day 22. Control 
group consisted of non-manipulated animals. (a) Representative 
microphotographs of lung sections stained with hematoxylin/eosin and (B) 
lung inflammation score (see Materials and Methods); values represent the 
mean ± SD and are representative of two independent experiments. 
One-way ANOVA:  ••••p < 0.0001, different between groups (n = 5).
11
Mirotti et al. Alum-Based CpG Formulation
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 47
B and T lymphocytes (RAG-KO and MyD88+/+) reconstituted 
with MyD88-KO lymphoid cells revealed that the expression of 
MyD88 on myeloid cells was sufficient to prevent Th2-mediated 
responses. Regarding the role of MyD88 and TRIF pathways 
of TLR signaling in adjuvant activity, Longhi et al. found that 
poly IC, a TLR3 agonist that signals via the TRIF pathway, was 
a superior adjuvant than CpG in a model of DC-targeted HIV 
gag protein vaccine in mice for development of Th1 CD4+ T cell 
responses (26). However, our results with CpG and those previ-
ously reported by us with MPLA, a TRIF-biased TLR4 agonist 
or with poly IC adsorbed onto Alum emphasize the role of the 
MyD88 pathway in preventing Th2 sensitization (7, 8). Thus, it 
appears that different immunological mechanisms are operating 
depending on whether the antigen is directly targeted to DCs or 
adsorbed onto Alum/TLR agonist-based formulations.
Several reports support a major influence of TLR signal-
ing in antigen presentation by DCs and regulation of antigen 
immunogenicity. In line with our work, it was shown that TLR 
ligands could activate DCs to release an uncharacterized MyD88-
dependent negative signal that impairs Th2 cell development 
(27). It has been demonstrated in  vitro that TLR controls the 
generation of T cell receptor ligands derived from endocytosed 
cargo, suggesting that TLR signaling via MyD88 in DC affects 
the antigen presentation process (28–30). We anticipate that 
Alum might function as a physical depot for slow release of a 
complex particulate matter containing CpG and OVA, allowing a 
continuous and/or differential modulation of antigen presenting 
cell activity that prevent the generation of necessary signals to 
accomplish Th2 sensitization. In the same vein, Yarovinsky et al. 
showed that selective responsiveness to a protein from Toxoplasma 
gondii, which signals thorough TLR11, required both TLR signal-
ing and MHC-II recognition acting in cis for the induction of 
IFNγ-secreting CD4+ T cells (31). It is noteworthy that, in our 
model, impairment of Th2 sensitization was more evident when 
CpG was adsorbed onto Alum than when it was administered 
separately from OVA/Alum as a bolus by s.c. or i.p. routes. Our 
results are in agreement with the work of Jankovic et al., which 
showed that absorption of IL-12 to Alum was more effective than 
IL-12 administered separately to induce Th1 responses against the 
HIVgp-120 envelope protein (32). Although antigen sensitization 
with exogenous IL-12 absorbed to Alum drives the immune 
response toward Th1 immunity, in our model sensitization with 
OVA/Alum/CpG resulted in a non-polarized (Th0-like) pattern. 
We reasoned that the concomitant induction of IL-10 by CpG 
could be curbing the development of polarized effector Th1 cells. 
Keeping with this hypothesis, it has been shown that the preven-
tion of bleomycin-induced pneumopathy by CpG treatment 
was critically dependent on IL-10 production (33). Therefore, 
we evaluated the role of IL-10 in our model in order to explain 
why sensitization with CpG did not result in Th1 immunity. We 
found that IL-10 was essential to prevent OVA-induced lung Th1 
immunity since sensitization with OVA/Alum/CpG in IL-10-KO 
mice resulted in an intense airway neutrophilic inflammation, 
augmented levels of IFNγ in BAL, and increased number of infil-
trating lung CD4+ T cells producing IFNγ. In addition, we showed 
that sensitization with OVA/Alum/CpG in absence of IL-10/
IL-12 results in the recruitment of Th17 effector/inflammatory T 
and known to exert inhibitory activity on allergic inflammation 
(13, 18). However, this was not the case since CpG also inhibited 
allergic inflammation in type I IFN receptor-KO mice.
Activation of the enzyme IDO by CpG was another mechanism 
proposed for the inhibition of allergic asthma (20). Recently, it 
was shown that CpG signaling through the TRIF pathway inhib-
ited allergic bronchopulmonary aspergillosis via IDO activity 
(13). However, in our model, the inhibition of Th2 sensitization 
by CpG was preserved in animals treated with 1-MT, an inhibi-
tor of IDO activity. In addition, IDO activity was not increased 
in the lungs of CpG-treated animals. We did not investigate the 
involvement of the TRIF pathway, because we found that MyD88 
signaling was essential for CpG-mediated inhibition of allergic 
sensitization. In addition, experiments with mice lacking adaptive 
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cells into the lung. It is important to distinguish the role of IL-10 
in the sensitization phase versus effector phase. We showed that 
during the effector phase, IL-10 is associated with Th2-mediated 
airway inflammation while during the sensitization phase IL-10 
production inhibits the development of effector T cells and as 
consequence OVA challenge does not result in airway inflamma-
tion. However, in IL-10-KO mice, OVA/Alum/CpG sensitization 
induces effector T cells that after OVA challenge are recruited to 
the lung and mediate airway inflammation dominated by IFNγ 
production (Th1-like). Therefore, it appears that sensitization 
with OVA/Alum/CpG does not primes for Th2 immunity but for 
Th1/Th17-like immunity that is not developed due to the regula-
tory/inhibitory effect of IL-10. Notably, sensitization with CpG 
in WT mice did not result in Th1 lung immunity after the OVA 
challenge, although it increased OVA-specific IgG2c antibodies, 
showing a dichotomy between cellular and humoral immune 
responses. This difference might be related to the emergence of 
distinctive T helper cell populations such as T follicular helper 
cells, related with B cell help in lymphoid organs versus activated/
effector Th1 cells that mediate tissue inflammation. However, we 
also found increased production of IgG2c in IL-12 and IFNγ-KO 
mice (data not shown) as well as in IL-10/IL12-KO mice, indicat-
ing that IgG2c is not solely regulated by the IL-12/IFNγ.
In summary, we found that absorption of CpG to Alum blocks 
Th2 sensitization signaling via MyD88 and IL-10 molecules. In 
WT mice, this type of sensitization results in a non-polarized 
immune phenotype revealed by the lack of effector/inflammatory 
T helper cell appearance in the lung, depressed IgE responses, and 
enhanced OVA-specific IgG2c antibodies. However, in IL-10-KO 
animals, this type of sensitization results in IFNγ-dominated lung 
inflammation and further increase in IgG2c production, while in 
IL-10/IL-12 double-KO mice, IL-17 production in lung predomi-
nates. Therefore, depending on both MyD88 pathway activation 
and IL-10 plus IL-12 production, CpG adsorbed to Alum induces 
a spectral T helper  sensitization, raging from non-polarized to 
Th1/Th17-like phenotypes.
A number of TLR ligands are currently under development 
for vaccine formulations or inflammatory disorders treatment (4, 
34). In fact, CpG has been extensively studied and shown to be 
beneficial in mouse and primate models of asthma as well as in 
human clinical trials (35, 36). Interestingly, it has been reported 
that administration of allergen adsorbed to Alum reduced 
allergen-specific IgE antibodies in atopic patients (37). Also, sub-
cutaneous administration of a ragweed-TLR9 agonist vaccine was 
clinically effective in allergic rhinitis treatment (38). Moreover, a 
novel TLR9 agonist showed clinical efficacy in persistent allergic 
asthma (39).
Collectively, our work highlights the molecular pathways 
and the adjuvant properties of Alum/CpG-based formulation, 
which can be potentially exploited in the design of vaccines or 
immunotherapies for allergy or infectious diseases.
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FigUre s1 | The 129 WT, 129 svgr (γ receptor)-KO, or 129 aBr (α/β 
receptor)-KO mice were sensitized with OVa/alum or OVa/alum/cpg on 
days 0 and 7 and challenged with OVa on days 14 and 21. Samples 
obtained on day 22. (a) Total cell and (B) eosinophil cell counts in BAL; (c) IL-5 
levels of in BAL; (D) total IgE and (e) OVA-specific IgE serum levels. Values 
represent the mean ± SD and are representative of three independent 
experiments. One-way ANOVA: *p < 0.05; **p < 0.01; ***p < 0.001; 
****p < 0.0001, difference between OVA/Alum and Ova/Alum/CpG (n = 5).
FigUre s2 | cpg attenuates airway allergic responses independently of 
indoleamine 2,3-dioxygenase (iDO) activity. C57BL/6 WT mice were 
sensitized with OVA/Alum or with OVA/Alum/CpG on days 0 and 7 and 
challenged with OVA on days 14 and 21. OVA/Alum/CpG groups were treated or 
not with 1-methyltryptohan (1-MT) incorporated in pellet, or in Alum or given i.p. 
(a) Total cell and (B) eosinophil cell counts in BAL, (c) kynurenine concentration 
in the lung; (D) total IgE and (e) OVA-specific IgE in serum levels. Values 
represent the mean ± SD and are representative of three independent 
experiments. One-way ANOVA: *p < 0.05; **p < 0.01; ***p < 0.001; different 
from OVA/Alum (n = 5).
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